Synthesis and P2Y₂ receptor agonist activities of uridine 5'-phosphonate analogues by Van Poecke, Sara et al.
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We explored the influence of modifications of uridine 5’-methylenephosphonate on biological 
activity at the human P2Y2 receptor. Key steps in the synthesis of a series of 5-substituted 
uridine 5’-methylenephosphonates were the reaction of a suitably protected uridine 5'-
aldehyde with [(diethoxyphosphinyl)methylidene]triphenylphosphorane, C-5 bromination and 
a Suzuki–Miyaura coupling. These analogues behaved as selective agonists at the P2Y2 
receptor, with three analogues exhibiting potencies in the submicromolar range. Although 
maximal activities observed with the phosphonate analogues were much less than observed 
with UTP, high concentrations of the phosphonates had no effect on the stimulatory effect of 





Extracellular purine and pyrimidine nucleosides and nucleotides act as messengers via 
specific receptors on the plasma membrane. These receptors exist in two families: P1 
receptors (also termed adenosine receptors) activated by adenosine and P2 receptors activated 
by adenosine 5’-tri- or diphosphate (ATP or ADP) and/or uridine 5’-tri- or diphosphate (UTP 
or UDP). P2 receptors are further divided as P2X and P2Y receptors, which are ligand-gated 
ion channels and G protein-coupled receptors (GPCRs), respectively.
1,2,3,4
 At least eight 
different subtypes of P2Y receptors are known, i.e. P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, 
P2Y13 and P2Y14. The missing numbers belong to non-mammalian receptors, which may be 




The various human P2Y receptor subtypes are activated by different physiological 
nucleotides. The human P2Y1, P2Y12, and P2Y13 receptors are activated preferentially by 
ADP, while the human P2Y11 receptor is activated preferentially by ATP. The human P2Y4, 
P2Y6, and P2Y14 subtypes respond exclusively to various uracil nucleotides, and the human 
P2Y2 receptor is activated by UTP and ATP with similar potency. The P2Y receptors are 
preferentially coupled to heterotrimeric G proteins of the Gq (P2Y1 - P2Y11) or Gi (P2Y12 - 
P2Y14) families, to stimulate phospholipase C (PLC) or to inhibit adenylyl cyclase (AC), 
respectively. The P2Y11 receptor is also coupled to Gs proteins. 
The P2Y2 receptor is the most widely studied uracil nucleotide receptor.
5
 It is broadly 
distributed throughout the body and is most prominently expressed in the lung, heart, skeletal 
muscle, spleen, kidney, and liver.
6,7 
The P2Y2 receptor is known to play important 
physiological roles in epithelial cells of the lung, gastrointestinal tract and the eye, and 
therefore, it is under investigation as a therapeutic target. Agonists are promising for treatment 
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of cystic fibrosis, cancer and dry eye syndrome,
8,9
 while P2Y2 antagonists might have anti-
inflammatory
10
 and neuroprotective effects.
11 
The major limitations associated with known agonists for the P2Y2 receptor are (i) the lack of 
selectivity vs. closely related P2Y receptor subtypes and (ii) their fast degradation by 
nucleotide-hydrolyzing ecto-enzymes, which results in a relative short duration of action.
5
 In 
that context, we recently explored to what extent replacement of the α-phosphate group of 
UTP by an isosteric phosphonate affected P2Y2 receptor activity.
9
 Since the carbon-
phosphorus bond cannot be hydrolyzed, this analogue was expected to exhibit prolonged 
metabolic stability. While we initially focused on a diphosphophosphonate mimic of UTP (2), 
it was fortuitously discovered that its synthetic precursor 3 was also capable of activating the 
P2Y2 receptor but was inactive at the P2Y4 receptor (Figure 1).
9 
1: X = O (UTP)































Figure 1. Structure of UTP (1), diphosphophosphonate 2, and 5’-methylenephosphonate 3. 
 
In this study, we explore the influence of further modifications of the 5’-
methylenephosphonate 3 on activity at the P2Y2 receptor. A patent application from Astra-
Zeneca indicated that incorporation of a large semiplanar, hydrophobic aromatic ring at 
position 5 of thiouridine triphosphate may be accommodated by the P2Y2 receptor but tends 
to preclude the conformational change required for receptor activation.
12
 Therefore, we 
introduced several smaller (hetero)aromatic substituents at the 5-position of analogue 3 to 
enhance binding but still allow for receptor activation. To sort out the influence of 
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replacement of the 2’-OH group of 3, we envisaged the synthesis of a 2’-chloro and a 2’-
amino analogue. Besides establishing possible interactions with the target receptor, a 2’-
chloro substituent may impact on the furanose ring conformation. In the case of UTP, a 2’-
amino modification was associated with increased P2Y2 selectivity while maintaining 
excellent potency.
13
 To assess the influence of rigidifying the ribofuranose conformation of 3, 
an N-methanocarba analogue was synthesized. Finally, another phosphonate bioisoster of 
uridine 5’-monophosphate (UMP), obtained by the inversion of the 4’-CH2-O group of UMP, 
was also explored. Transforming a phosphate moiety ((RO)2P(O)-O-C-) to its isomeric 
catabolically stable phosphonomethyl ether ((RO)2P(O)-C-O-) has proven to be a successful 
strategy in the development of antiviral drugs.
14
 
Results and Discussion 
Chemistry 
Different methods for the preparation of isosteric phosphonate analogues of nucleoside 
phosphates have been reported. Most often these involve a Wittig-type
15
 or an Arbuzov
16
 
reaction. In addition, Barton et al.
17
 published a radical approach for the introduction of the 
carbon-phosphorous bond. We decided to follow the method described by Xu et al.
18
 in which 
the isosteric analogue was prepared by treatment of a suitably protected uridine 5'-aldehyde 
with a stabilized [Ph3P=CHPO(OEt)2] ylide. Hydrogenation of the obtained olefin in MeOH 
using a 10% palladium on carbon catalyst gave access to the known compound 4.
9
 C-5 
selective NBS-mediated bromination of this intermediate followed by a Suzuki–Miyaura 
coupling with a number of commercial aryl and heteroaryl boronic acids gave access to a 
series of C-5 substituted analogues. The latter transformation took place in a DMF–H2O 
solution and was catalyzed by Pd(PPh3)4. Sodium carbonate was used for the activation of the 
boronic acids.
19
 One-pot deprotection of the phosphonate diester and the 2’,3’-O-
6 
 
isopropylidene group by consecutive treatment with TMSBr and TFA afforded the desired 













































a: R = phenyl
b: R = naphthalen-2-yl
c: R = 4- fluorophenyl
d: R = styryl
e: R = p-tolyl
f : R = furan-2-yl
g: R = thien-2-yl
h: R = benzothiophen-2-yl  
Scheme 1. Reagents and conditions. (a) NBS, DMF, rt, overnight, 79%; (b) R-B(OH)2, 
Na2CO3, Pd(PPh3)4, DMF, H2O, reflux, 4 h, 39-76%; (c) (i) TMSBr, CH2Cl2, rt, overnight; 
(ii) TFA, H2O, rt, 4 h, 11-78%. 
The synthesis of 2’-substituted 5’-methylenephosphonates 12 and 14 started from 
intermediate 4 (Scheme 2). Following deprotection of the 2’ and 3’ hydroxyl groups of 4, 
2’,2-O-anhydro analogue 9 was formed using thionyl chloride in CH3CN followed by the 
addition of NaOAc.
20
 Introduction of an amino group at the 2’ position was accomplished via 
opening of the anhydro-derivative 9 with NaN3 in DMF. Interestingly, these conditions 
caused concomitant incomplete hydrolysis of the phosphonate ester to afford 10 as reported 
previously by Holy.
21
 Staudinger reduction of the azide followed by deprotection of mono 
ethylphosphonate 11 resulted in the desired 2’-amino-2’-deoxyuridine-5’-phosphonate 
analogue 12. Similarly, treatment of 9 with a 2 N HCl in diethyl ether solution followed by 




Scheme 2. Reagents and conditions. (a) 50% aq. HCOOH, rt, 4.5 h, 57%; (b) (i) thionyl 
chloride, CH3CN; (ii) CH3COONa, DMF, 85 °C, 92 %; (c) NaN3, DMF, 150 °C, overnight, 
88%; (d) PPh3, THF, H2O, rt, overnight, quant.; (e) TMSBr, CH2Cl2, rt, overnight, 78% for 
2’-amino and 58% for 2’-chloro; (f) 2 N HCl in Et2O-dioxane (3:1), rt, overnight, 54%.  
The synthetic procedure for N-methanocarba analogue 17 is depicted in Scheme 3. An initial 
Mitsunobu base coupling reaction of previously reported alcohol 15
22
 using 
triphenylphosphine, diisopropyl azodicarboxylate and 3-N-benzoyluracil
23
 followed by a 
debenzoylation using 6 N NH3/MeOH gave phosphonate diester 16 in 24% overall yield. 
Simultaneous deprotection of the phosphonate diester and the 2’,3’-O-isopropylidene group 
using freshly opened iodotrimethylsilane
24




Scheme 3. Reagents and conditions. (a) (i) Triphenylphosphine, 3-N-benzoyluracil, 
diisopropyl azodicarboxylate, anh. THF; (ii) 6 N NH3/MeOH, 50 ºC, 24% (over two steps); 
(b) iodotrimethylsilane, anhyd. CH2Cl2, 19%.  
The synthesis of 4’-O-CH2 phosphonate analogue 22 started from 2',3'-dideoxy-3',4'-
didehydro-β-D-erythrofuranosyl)uracil 18 (Scheme 4).
25
 Treatment of this glycal with 
phenylselenyl chloride at -70 °C followed by the addition of silver perchlorate in the presence 
of diethyl (hydroxymethyl)phosphonate afforded phosphonate 19 in 35% overall yield. 
Assignment of the stereoarrangement in 19 was based on mechanistic considerations.
26
 
Phosphonate 19 was further transformed into olefin 20 via sodium periodate oxidation of 
selenium and subsequent elimination. OsO4-promoted dihydroxylation in the presence of N-
methylmorpholine-N-oxide followed by TMSBr hydrolysis of the phosphonate ester groups 
provided compound 22 in moderate yield. A positive NOE was observed between the H-1’ 
and H-4’ of compound 20, confirming the cis stereoarrangement of the uracil base and the 




Scheme 4. Reagents and conditions. (a) (i) PhSeCl, CH2Cl2, -70 °C, 1 h; (ii) 
HOCH2PO(OEt)2, AgClO4, CH2Cl2, CH3CN, -70 °C → 0 °C, 15 min, 35%; (b) NaIO4, 
NaHCO3, MeOH, rt, 1 h then 80 °C, 75 min, 68%; (c) OsO4, NMO, acetone-H2O (5:1), rt, 48 
h, 60%; (d) TMSBr, 2,6-lutidine, DMF, 0 °C → rt, overnight, 50%. 
 
Pharmacological Evaluation 
Activities of analogues at the P2Y2 receptor were determined measuring PLC-dependent 
phosphoinositide hydrolysis in 1321N1 human astrocytoma cells stably expressing the human 
P2Y2 receptor (P2Y2-1321N1 cells).
27,28
 As previously shown for UTP and UDP
27
, none of 
the phosphonate analogues reproducibly promoted inositol phosphate accumulation in wild-
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Figure 2. Inositol phosphate accumulation in (A) wild type 1321N1 human astrocytoma cells 
or in 1321N1 cells stably expressing the human (B) P2Y2, (C) P2Y4, or (D) P2Y6 receptor. 
The concentration of all phosphonate analogues was 100 M, of carbachol was 100 M, of 
UTP was 100 nM, and UDP was 1µM. [
3
H]inositol phosphate accumulation was quantified as 
described in Methods. The results are presented as the percent of response observed with 
carbachol (A), UTP (B,C), or UDP (D). Values are presented as the mean ± S.E.M. and are 
the average of results obtained in at least three separate experiments. 
In contrast, quantification of inositol phosphate accumulation in P2Y2 receptor-expressing 
1321N1 cells revealed that the newly synthesized 5’-methylenephosphonate analogues are 
P2Y2 receptor agonists (Fig 2B), although none of the analogues produced maximal effects at 
100 M concentration as great as UTP. Given the novel activity observed with these 
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phosphonate analogues at the P2Y2 receptor, we also determined whether they interacted with 
the UTP-activated P2Y4 receptor or the UDP-activated P2Y6 receptor. Little or no 
reproducible stimulation was observed over basal activity for any of these analogues in 
1321N1 human astrocytoma cells stably expressing the human P2Y4 (Fig. 2C) or human P2Y6 
(Fig. 2D) receptors. 
Full concentration effect curves were generated in P2Y2-1321N1 cells with each of the 
analogues to more clearly assess their maximal effects relative to UTP and to establish their 
relative potencies as P2Y2 receptor agonists. To enhance clarity of comparison of the relative 











































































































































Figure 3. Concentration dependent activation of the P2Y2 receptor by phosphonate nucleotide 
derivatives. Accumulation of [
3
H]inositol phosphates was quantified as described under 
Methods. The data are plotted as percent of the maximal response observed with UTP, are 
presented as the mean ± S.E.M, and are representative of results obtained in three or more 
separate experiments.  
The 5-modified uridine 5’-phosphonate analogues activated the P2Y2 receptor with a range of 
apparent potencies, and the maximal effect observed with each of these molecules was only 
40-55% of that observed with UTP (Fig. 3 and Table 1). The most potent agonists were the 5-
(4-fluorophenyl) (7c), thien-2-yl (7g), and 5-(2-furanyl) (7f) analogues, which exhibited 
potencies in the submicromolar range (Table 1). 
Compound EC50, µM Max response 
1 0.02 ± 0.003  100 
3 5.1 ± 0.9 32 ± 9 
7a 1.5 ± 0.5  53 ± 7 
7b 2.1 ± 0.6 54 ± 7 
7c 0.4 ± 0.2 43 ± 5 
7d 3.1 ± 1.3 41 ± 12 
7e 1.0 ± 0.8 41 ± 7 
7f 0.7 ± 0.3 45 ± 5 
7g 0.5 ± 0.3 35 ± 5 
7h >20 45 ± 5 
12 >20 9 ± 5 
14 >20 9 ± 8 
17 4.0 ± 0.7 nd 
22 >20 19 ± 9 
Table 1. Relative potencies and maximal effects of UTP and phosphonate analogues at the 
human P2Y2 receptor. Agonist potency (EC50 value) and maximal response relative to UTP 
was determined for each analogue in P2Y2-1321N1 cells as described under Methods. The 
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data are presented as the mean ± S.E.M of values obtained from 3-6 separate experiments 
with each analogue.  
Both 2’-modified analogues (12 and 14) were essentially inactive at the P2Y2 receptor. The 
negative impact of the replacement of a 2’-OH by a 2’-NH2 group may indicate that these 
phosphonates have a different mode of binding to the P2Y2 receptor, since a similar 
modification on UTP was well tolerated.  
Conformationally constrained compound 17 behaved as a low efficacy P2Y2 agonist 
compared to UTP. This indicated that a (N) conformation of a ribose-like moiety in this series 
of nucleoside monophosphonates is compatible with the observed biological effect. Likewise, 
compound 22 was significantly less potent than the lead phosphonate indicating that 
replacement of the 5’-CH2 group by an oxygen tends to reduce agonist activity.  
The activities of two of the most potent new compounds 7c and 7f were directly compared in 
the same experiments to the 5-unsubstituted parent compound 3 (Fig. 4). Both analogues 
produced maximal effects at the P2Y2 receptor that were similar to that of 3, but were 





































Figure 4. Comparison of the concentration dependence of the most potent phosphonates for 
activation of the P2Y2 receptor. Accumulation of [
3
H]inositol phosphates was quantified as 
described under Methods. The data are plotted as percent of the maximal response observed 
with UTP, are presented as the mean ± S.E.M., and are representative of results obtained in 
three separate experiments. 
The idea that these modified uridine 5’-phosphonate analogues are orthosteric ligands that 
exhibit less intrinsic efficacy than UTP was examined by assessing their capacity at high 
concentrations to inhibit the effect of a near-maximal concentration of UTP (Fig. 5A). No 
inhibitory effect on the action of UTP was observed with any of these phosphonate analogues. 
Concentration effect curves for UTP also were carried out in the absence and presence of a 
high (100 M) concentration of 7c or 7f to determine whether the activity of these molecules 
was consistent with that of agonists acting at the orthosteric or an allosteric site of the P2Y2 
receptor. As illustrated in Fig. 5, neither 7c nor 7f affected the potency of UTP. These results 
are consistent with the idea that the uridine 5’-phosphonate analogues act at an allosteric site 




Figure 5. Effect of high concentrations of phosphonate analogues on the P2Y2 receptor-
mediated activity of UTP. (A) The effects of 100 M concentrations of the indicated 
phosphonates were tested in the presence of 100 nM UTP in P2Y2-1321N1 cells as described 
in Methods. (B) Concentration response curves for UTP were generated in P2Y2-1321N1 cells 
in the absence or presence of 100 M 7c or 7f. [
3
H]inositol phosphate accumulation was 
quantified as described in Methods. The data are presented as the mean ± S.E.M. and are 




The furanose ring of nucleotides displays a characteristic equilibrium between two favored 
puckering conformations, i.e. the (N) and South (S) state.
29
 Davies et al.
30
 derived the 
following equations that relate the fraction of the (N) conformer XN with the values of the 
vicinal three scalar couplings that can be measured between the protons of ring: 
JH1’,H2’ = 9.3 (1-XN) 
JH2’,H3’ = 4.6XN + 5.3 (1-XN) 
JH3’,H4’ = 9.3XN 
To assess the impact of the presence of a substituent at the C-5 position of the uracil base on 
the relative proportions of (N) and (S) conformers, these scalar couplings were measured at 
five different temperatures for the 5-phenyl substituted uridine phosphonate 7a, while the 
same was done for the non-C-5 substituted uridine phosphonate 3. The fraction of the (N)-
type conformer was obtained by minimizing the sum of square difference between the 
experimental couplings and those calculated from the above equations. The results are shown 
in Table 1. 
Table 2. 
1
H NMR derived mole fraction of the (N)-type conformer of 3 and 7a at different 
temperatures.  
 XN 
T [°C] 3 7a 
20 55.5 52.9 
27 54.8 53.1 
35 54.4 54.1 
17 
 
42 54.1 53.8 
50 54.0 53.0 
For compound 3, the (N) and (S) conformers are nearly equally present, with a small 
preference for the (N). From Table 1, it appears that compound 7a has similar (N)/(S) 
populations as 3. It can therefore be concluded that the incorporation of a phenyl group at the 
C-5 position appears to have no effect on the conformational state of the ribofuranose ring. 
Interestingly, this is in contrast to the effect of implanting a phenyl ring at C-6 of the base as 
was published recently by Nencka et al.,
31 
that clearly shows an enhanced preference for the 
(N) conformation. A second aspect of the conformation is the orientation of the base relative 
to the ring structure, which is here assumed to be either syn (with the substituent pointing 
away from the ring) or anti (with the substituent pointing towards the ring). The NOESY 
spectrum of 3 confirmed that the anti rotamer could be adopted. However, when a bulky 
group is implanted at the C-5 position, it orients away from the ribose ring, meaning that in 
this case only the syn rotamer will be available. 
Conclusions 
In this study we explored the influence of modifications of uridine 5’-methylenephosphonate 
(3) on activity at the human P2Y2 receptor. A Suzuki–Miyaura coupling of a suitable 5-bromo 
precursor with aryl and heteroaryl boronic acids allowed generation of a small series of C-5 
substituted analogues of 3. All 5-modified analogues caused P2Y2 receptor-dependent inositol 
phosphate accumulation. Within this series, 5-(2-furanyl) (7f), 5-(4-fluorophenyl) (7c), and 
thien-2-yl (7g) substitutions afforded the highest potencies. Interestingly, none of the 
phosphonate analogues exhibited the same maximal activity as UTP, and these analogues 
failed to inhibit activity of UTP down to the level of activity observed with the 5-modified 
analogues alone as would be expected for classical partial agonists acting at the orthosteric 
18 
 
binding pocket. Indeed, no change in the concentration effect curve to UTP occurred in the 
presence of supramaximal concentrations of 7c or 7f. These results are consistent with the 
concept that these analogues allosterically activate the P2Y2 receptor in a manner that has no 
obvious influence on the effects of UTP mediated through its orthosteric binding site. 
Although our observations strongly suggest allosteric regulation by the phosphonate 
analogues, they do not prove it, and the lack of availability of a radioligand for direct 
assessement of the orthosteric binding site prevents more confident conclusions about their 
mechanism of action. By altering the sugar part of 3, we showed that the SAR in the 
phosphonate series does not fully parallel that observed in the triphosphate class, further 
suggesting that the current phosphonates may bind at a site that differs from the cognate 
agonist binding pocket.  
Experimental Section 
Chemical Synthesis 
All reagents were from standard commercial sources and of analytic grade. Precoated Merck 
silica gel F254 plates were used for TLC, spots were examined under ultraviolet light at 254 
nm and further visualized by sulfuric acid-anisaldehyde spray. Column chromatography was 






P NMR spectra were recorded in CDCl3, DMSO-d6, CD3OD or D2O on a Varian 
Mercury 300 MHz and a Bruker 700 MHz spectrometer. Chemical shifts are given in parts 




C and to external D3PO4 for 
31
P. Structural assignment was confirmed with COSY and DEPT. All signals assigned to 
hydroxyl groups were exchangeable with D2O. Exact mass measurements were performed on 
a Waters LCT Premier XETM Time of flight (TOF) mass spectrometer equipped with a 
19 
 
standard electrospray ionization (ESI) and modular LockSpray TM interface. Samples were 





To a solution of compound 4
9
 (399 mg, 0.95 mmol) in DMF (8 mL) was added N-
bromosuccinimide (NBS, 187 mg, 1.05 mmol) under N2. The reaction mixture was stirred at 
room temperature for 16 hours. DMF was removed in vacuo and the residue was purified by 
column chromatography (CH2Cl2/MeOH 95:5) to afford compound 5 (376 mg, 79%) as a 
colorless oil. 
1
H NMR (300 MHz, DMSO-d6): δ 1.20-1.28 (m, 9H, OCH2CH3, CH3), 1.47 (s, 
3H, CH3), 1.69-1.92 (m, 4H, H-5’, H-6’), 3.90-4.04 (m, 5H, OCH2CH3, H-4’), 4.64-4.67 (m, 
H-3’), 5.04 (dd, J = 2.1, 6.6 Hz, H-2’), 5.73 (d, J = 2.1 Hz, H-1’), 8.23 (s, H-6), 11.91 (s, 3-
NH). 
31
P NMR (DMSO-d6): δ 31.53. 
13
C-NMR (75 MHz, DMSO-d6): δ 16.25, 16.32 
(OCH2CH3), 20.83 (d, J = 140 Hz, C-6’), 25.24, 27.00 (C(CH3)2), 25.70 (C-5’), 60.91, 61.00 
(OCH2CH3), 82.61 (C-3’), 83.38 (C-2’), 85.65 (d, J = 17.9 Hz, C-4’), 91.77 (C-1’), 96.12 (C-
5), 113.49 (C(CH3)2), 142.53 (C-6), 149.56 (C-2), 159.23 (C-4). HRMS (ESI) for 
C17H27BrN2O8P [M+H]
+
 found, 497.0697; calcd, 497.0683. 
General procedure for the synthesis of 5-modified nucleoside phosphonates via Suzuki-
Miyaura coupling (6a-h) 
A mixture of compound 5 (1 equiv.), aryl boronic acid (2 equiv.), Pd(PPh3)4 (0.1 equiv.) and 
Na2CO3 (3.3 equiv.) in DMF and degassed H2O was heated (± 130 °C, oil bath) under argon 
for 6 h or until TLC indicated consumption of all starting material. The mixture was then 
concentrated and co-distilled with toluene. The residue was purified by column 





Reaction of compound 5 (78 mg, 0.16 mmol) with phenylboronic acid (39 mg, 0.32 mmol), 
Pd(PPh3)4 (18 mg, 0.016 mmol) and Na2CO3 (55 mg, 0.52 mmol) in DMF (4 mL) and 
degassed H2O (0.5 mL) was performed as described in the general procedure. Purification of 
the crude mixture on a silica gel column (CH2Cl2/MeOH 95:5) afforded compound 6a as a 
colorless oil (33 mg, 43%). 
1
H NMR (300 MHz, DMSO-d6): δ 1.18-1.23 (m, 6H, OCH2CH3), 
1.30 (s, 3H, CH3), 1.49 (s, 3H, CH3), 1.74-1.89 (m, 4H, H-5’, H-6’), 3.91-4.02 (m, 5H, 
OCH2CH3, H-4’), 4.67-4.71 (m, H-3’), 5.14 (dd, J = 2.4, 6.6 Hz, H-2’), 5.85 (d, J = 2.1 Hz, 
H-1’), 7.29-7.41 (m, 3H, Ph), 7.52-7.55 (m, 2H, Ph), 7.91 (s, H-6), 11.62 (s, 3-NH). 
31
P NMR 
(DMSO-d6): δ 31.55. 
13
C NMR (75 MHz, DMSO-d6): δ 16.22, 16.30 (OCH2CH3), 20.81 (d, J 
= 140 Hz, C-6’), 25.26, 27.03 (C(CH3)2), 25.80 (C-5’), 60.94, 60.98 (d, J = 6.3 Hz, 
OCH2CH3), 82.76 (C-3’), 83.42 (C-2’), 85.55 (d, J = 17.9 Hz, C-4’), 91.96 (C-1’), 113.44, 
113.85 (C-5, (C(CH3)2)), 127.39, 128.05, 128.27, 132.69, 140.40 (Ph,C-6), 149.70 (C-2), 
162.21 (C-4). HRMS (ESI) for C23H32N2O8P [M+H]
+
 found, 495.1891; calcd, 495.1891. 
1-[5’,6’-Dideoxy-6’-(diethoxyphosphinyl)-2’,3’-O-isopropylidene-β-D-ribo-
hexofuranosyl]-5-(naphthalen-2-yl)uracil (6b) 
Reaction of compound 5 (63 mg, 0.13 mmol) with naphthalene-1-boronic acid (45 mg, 0.25 
mmol), Pd(PPh3)4 (15 mg, 0.013 mmol) and Na2CO3 (44 mg, 0.42 mmol) in DMF (3 mL) and 
degassed H2O (0.4 mL) was performed as described in the general procedure for the synthesis 
of 5-modified phosphonates. Purification of the crude mixture on a silica gel column 
(CH2Cl2/MeOH 96:4) afforded compound 6b as a colorless solid (42 mg, 61%). 
1
H NMR 
(300 MHz, DMSO-d6): δ 1.19 (dt, 6H, J = 1.5, 7.2 Hz, OCH2CH3), 1.31 (s, 3H, CH3), 1.50 (s, 
3H, CH3), 1.74-1.91 (m, 4H, H-5’,H-6’), 3.90-4.04 (m, 5H, OCH2CH3, H-4’), 4.71 (dd, J = 
21 
 
4.5 Hz, J = 6.3 Hz, H-3’), 5.18 (dd, J = 2.4, 6.6 Hz, H-2’), 5.87 (d, J = 2.1 Hz, H-1’), 7.49-
7.55 (m, 2H, naphthyl), 7.69 (dd, J = 1.8, 8.4 Hz, naphthyl), 7.90-7.95 (m, 3H, naphthyl), 
8.06 (s, H-6), 8.12 (d, J = 1.2 Hz, naphthyl), 11.69 (s, 3-NH). 
31
P NMR (DMSO-d6): δ 16.21, 
16.28 (OCH2CH3), 20.81 (d, J = 140 Hz, C-6’), 25.30, 27.05 (C(CH3)2), 25.88 (C-5’), 61.01 
(OCH2CH3), 82.80 (C-3’), 83.47 (C-2’), 85.56 (C-4’), 92.28 (C-1’), 113.40, 113.66 (C-5, 
(C(CH3)2)), 126.09, 126.19, 126.49, 126.82, 127.28, 127.42, 127.94, 130.42, 132.12, 132.78, 
140.89 (naphthyl, C-6), 149.80 (C-2), 162.51 (C-4). HRMS (ESI) for C27H34N2O8P [M+H]
+
 
found, 545.2076; calcd, 545.2047. 
1-[5’,6’-Dideoxy-6’-(diethoxyphosphinyl)-2’,3’-O-isopropylidene-β-D-ribo-
hexofuranosyl]-5-(4-fluorophenyl)uracil (6c) 
Reaction of compound 5 (78 mg, 0.16 mmol) with 4-fluorophenyl boronic acid (44 mg, 0.31 
mmol), Pd(PPh3)4 (18 mg, 0.016 mmol) and Na2CO3 (54 mg, 0.51 mmol) in DMF (4 mL) and 
degassed H2O (0.5 mL) was performed as described in the general procedure for the synthesis 
of 5-modified phosphonates. Purification of the crude mixture on a silica gel column 
(CH2Cl2/MeOH 95:5) afforded compound 6c as a colorless solid (56 mg, 70%). 
1
H NMR (300 
MHz, DMSO-d6): δ 1.18 (dt, 6H, J = 0.9, 7.2 Hz, OCH2CH3), 1.27 (s, 3H, CH3), 1.47 (s, 3H, 
CH3), 1.72-1.89 (m, 4H, H-5’, H-6’), 3.92-4.02 (m, 5H, OCH2CH3, H-4’), 4.69 (dd, J = 4.8, 
6.6 Hz, H-3’), 5.14 (dd, J = 2.4, 6.9 Hz, H-2’), 5.83 (d, J = 2.4 Hz, H-1’), 7.19-7.25 (m, 2H, 
Ph), 7.57-7.63 (m, 2H, Ph), 7.92 (s, H-6), 11.64 (s, 3-NH). 
31
P NMR (DMSO-d6): δ 31.56. 
13
C 
NMR (75 MHz, DMSO-d6): δ 16.22, 16.29 (OCH2CH3), 20.82 (d, J = 139 Hz, C-6’), 25.27, 
27.03 (C(CH3)2), 25.85 (C-5’), 60.95, 60.99 (d, J = 6.0 Hz, OCH2CH3), 82.77 (C-3’), 83.40 
(C-2’), 85.56 (d, J = 17.9 Hz, C-4’), 92.01 (C-1’), 112.89, 113.46, 114.74, 115.02 (Ph, C-5, 
(C(CH3)2)), 129.08, 130.24, 130.35 (Ph), 140.45 (C-6), 149.71 (C-2), 159.94 (Ph), 162.26 (C-
4). HRMS (ESI) for C23H31FN2O8P [M+H]
+





Reaction of compound 5 (91 mg, 0.18 mmol) with trans-2-phenylvinyl boronic acid (56 mg, 
0.37 mmol), Pd(PPh3)4 (21 mg, 0.018 mmol) and Na2CO3 (64 mg, 0.60 mmol) in DMF (4 
mL) and degassed H2O (0.5 mL) was performed as described in the general procedure for the 
synthesis of 5-modified phosphonates. Purification of the crude mixture on a silica gel column 
(CH2Cl2/MeOH 95:5) afforded compound 6d as a colorless solid (72 mg, 76%). 
1
H NMR 
(300 MHz, DMSO-d6): δ 1.18 (app dt, 6H, J = 1.2, 6.9 Hz, OCH2CH3), 1.28 (s, 3H, CH3), 
1.48 (s, 3H, CH3), 1.71-1.88 (m, 4H, H-5’, H-6’), 3.90-4.01 (m, 5H, OCH2CH3, H-4’), 4.68 
(dd, J = 4.8, 6.6 Hz, H-3’), 5.06 (dd, J = 2.4, 6.6 Hz, H-2’), 5.80 (d, J = 2.4 Hz, H-1’), 6.88 
(d, J = 16.2 Hz, styryl), 7.20-7.25 (m, styryl), 7.33 (d, 2H, J = 7.8 Hz, styryl), 7.43-7.48 (m, 
3H, styryl), 7.94 (H-6).
 31
P NMR (DMSO-d6): δ 31.51. 
13
C NMR (75 MHz, DMSO-d6): δ 
16.22, 16.30 (OCH2CH3), 20.83 (d, J = 140 Hz, C-6’), 25.29, 27.02 (C(CH3)2), 25.89 (C-5’), 
60.97, 61.01 (d, J = 6.3 Hz, OCH2CH3), 82.64 (C-3’), 83.49 (C-2’), 85.41 (d, J = 17.6 Hz, C-
4’), 91.34 (C-1’), 111.22 (C-5), 113.54 (C(CH3)2), 120.83, 125.99, 127.42, 128.32, 128.74, 
137.43 (styryl), 140.09 (C-6), 149.26 (C-2), 162.21 (C-4). HRMS (ESI) for C25H34N2O8P 
[M+H]
+
 found, 521.2049; calcd, 521.2047. 
1-[5’,6’-Dideoxy-6’-(diethoxyphosphinyl)-2’,3’-O-isopropylidene-β-D-ribo-
hexofuranosyl]-5-(p-tolyl)uracil (6e) 
Reaction of compound 5 (63 mg, 0.13 mmol) with 4-methylphenylboronic acid (36 mg, 0.25 
mmol), Pd(PPh3)4 (15 mg, 0.013 mmol) and Na2CO3 (45 mg, 0.42 mmol) in DMF (3 mL) and 
degassed H2O (0.4 mL) was performed as described in the general procedure for the synthesis 
of 5-modified phosphonates. Purification of the crude mixture on a silica gel column 
(CH2Cl2/MeOH 97:3) afforded compound 6e as a colorless solid (29 mg, 46%). 
1
H NMR (300 
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MHz, CDCl3): δ 1.24-1.33 (m, 9H, OCH2CH3, CH3), 1.54 (s, 3H, CH3), 1.72-2.07 (m, 4H, H-
5’, H-6’), 2.71 (s, 3H, p-tolyl), 4.01-4.13 (m, 5H, OCH2CH3, H-4’), 4.64 (dd, J = 4.5, 6.3 Hz, 
H-3’), 5.04 (dd, J = 2.1, 6.3 Hz, H-2’), 5.67 (d, J = 2.4 Hz, H-1’), 7.16-7.79 (m, 4H, p-tolyl), 
8.00 (H-6). 
31
P NMR (CDCl3): δ 31.27. HRMS (ESI) for C24H34N2O8P [M+H]
+
 found, 
509.2076; calcd, 509.2047. 
1-[5’,6’-Dideoxy-6’-(diethoxyphosphinyl)-2’,3’-O-isopropylidene-β-D-ribo-
hexofuranosyl]-5-(furan-2-yl)uracil (6f) 
Reaction of compound 5 (93 mg, 0.19 mmol) with furan-2-boronic acid (42 mg, 0.37 mmol), 
Pd(PPh3)4 (22 mg, 0.019 mmol) and Na2CO3 (65 mg, 0.62 mmol) in DMF (4.5 mL) and 
degassed H2O (0.6 mL) was performed as described in the general procedure for the synthesis 
of 5-modified phosphonates. Purification of the crude mixture on a silica gel column 
(CH2Cl2/MeOH 95:5) afforded compound 6f as a brown solid (36 mg, 40%). 
1
H NMR (300 
MHz, DMSO-d6): δ 1.16-1.28 (m, 6H, OCH2CH3) 1.28 (s, 3H, CH3), 1.48 (s, 3H, CH3), 1.76-
1.81 (m, 4H, H-5’, H-6’), 3.82-4.07 (m, 5H, OCH2CH3, H-4’), 4.58-4.68 (m, H-3’), 5.03-5.13 
(m, H-2’), 5.84-5.86 (m, H-1’), 6.50-6.54 (m, furanyl), 6.83-6.88 (m, furanyl), 7.61-7.66 (m, 
furanyl), 8.02 (app d, J = 4.8 Hz, H-6). 
31
P NMR (DMSO-d6): δ 31.63. 
13
C NMR (75 MHz, 
DMSO-d6): δ 16.29, 16.37 (OCH2CH3), 20.99 (d, J = 148 Hz, C-6’), 25.31, 27.07 (C(CH3)2), 
60.99, 61.11 (OCH2CH3), 82.83 (C-3’), 83.74 (C-2’), 85.95 (d, J = 7.5 Hz, C-4’), 92.37 (C-
1’), 105.72, 108.40 (furanyl), 111.73 (C-5), 113.46 ((C(CH3)2)), 128.83, 131.55 (furanyl), 
141.79 (C-6), 149.24 (C-2), 160.37 (C-4). HRMS (ESI) for C21H30N2O9P [M+H]
+
 found, 





Reaction of compound 5 (81 mg, 0.16 mmol) with thiophene-2-boronic acid (42 mg, 0.33 
mmol), Pd(PPh3)4 (19 mg, 0.016 mmol) and Na2CO3 (57 mg, 0.54 mmol) in DMF (4 mL) and 
degassed H2O (0.5 mL) was performed as described in the general procedure for the synthesis 
of 5-modified phosphonates. Purification of the crude mixture on a silica gel column 
(CH2Cl2/MeOH 95:5) afforded compound 6g as a colorless solid (32 mg, 39%). 
1
H NMR 
(300 MHz, DMSO-d6): δ 1.1-1.22 (m, 6H, OCH2CH3) 1.28 (s, 3H, CH3), 1.48 (s, 3H, CH3), 
1.68-1.91 (m, 4H, H-5’, H-6’), 3.90-3.97 (m, 5H, OCH2CH3, H-4’), 4.67-4.69 (m, H-3’), 
5.13-5.15 (m, H-2’), 5.82 (m, H-1’), 7.05-7.07 (m, thienyl), 7.46-7.47 (m, 2H, m, thienyl), 
8.20 (s, H-6). 
31
P NMR (DMSO-d6): δ 31.64. 
13
C NMR (75 MHz, DMSO-d6): δ 16.25, 16.33 
(OCH2CH3), 20.85 (d, J = 140 Hz, C-6’), 25.31, 27.07 (C(CH3)2), 60.99 (OCH2CH3), 82.87 
(C-3’), 83.57 (C-2’), 85.86 (C-4’), 93.79 (C-1’), 108.56 (C-5), 113.40 (C(CH3)2), 128.73-
138.33 (thienyl). HRMS (ESI) for C21H30N2O8PS [M+H]
+
 found, 501.1453; calcd, 501.1455. 
1-[5’,6’-Dideoxy-6’-(diethoxyphosphinyl)-2’,3’-O-isopropylidene-β-D-ribo-
hexofuranosyl]-5-(benzothiophen-3-yl)uracil (6h) 
Reaction of compound 5 (105 mg, 0.21 mmol) with 1-benzothiophen-3-ylboronic acid (77 
mg, 0.42 mmol), Pd(PPh3)4 (24 mg, 0.021 mmol) and Na2CO3 (74 mg, 0.70 mmol) in DMF (5 
mL) and degassed H2O (0.7 mL) was performed as described in the general procedure for the 
synthesis of 5-modified phosphonates. Purification of the crude mixture on a silica gel column 
(CH2Cl2/MeOH 95:5) afforded compound 6h as a brown solid (49 mg, 42%). 
1
H NMR (300 
MHz, CDCl3): δ 1.25-1.32 (m, 9H, OCH2CH3, CH3), 1.55 (s, 3H, CH3), 1.77-1.93 (m, 2H, H-
6’), 1.98-2.08 (m, 2H, H-5’), 4.02-4.12 (m, 5H, OCH2CH3, H-4’), 4.61 (t, J = 5.7 Hz, H-3’), 
5.00 (app d, J = 6.6 Hz, H-2’), 5.70 (app s, H-1’), 7.32-7.41 (m, 2H, benzothiophenyl), 7.46-
7.48 (m, benzothiophenyl), 7.54 (s, H-6), 7.67 (d, J = 7.8 Hz, benzothiophenyl), 7.86 (d, J = 
7.8 Hz, benzothiophenyl), 9.53 (br s, 3-NH). 
31
P NMR (CDCl3): δ 31.01. 
13
C NMR (75 MHz, 
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CDCl3): δ 16.52, 16.60 (OCH2CH3), 21.99 (d, J = 142 Hz, C-6’), 25.48, 27.31 (C(CH3)2), 
26.41 (C-5’), 61.81 (OCH2CH3), 83.43 (C-3’), 84.41 (C-2’), 86.64 (d, J = 17.9 Hz, C-4’), 
93.79 (C-1’), 110.69, 115.11 (C-5, (C(CH3)2)), 122.48, 123.08, 124.65, 124.71, 126.86, 
126.94, 137.70 (benzothiophenyl), 140.15, 140.39 (C-6, benzothiophenyl), 149.54 (C-2), 
162.12 (C-4). HRMS (ESI) for C25H32N2O8PS [M+H]
+
 found, 551.1620; calcd, 551.1612. 
1-[5’,6’-Dideoxy-6’-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-phenyluracil (7a) 
Phosphonic ester 6a (32 mg, 0.068 mmol) was dissolved in 1.4 mL of CH2Cl2 under argon 
and treated with TMSBr (18 μL, 1.35 mmol) and the solution was stirred overnight. The 
solvents were evaporated and the residue was co-distilled with toluene. Then, 0.7 mL of H2O 
was added followed by 1.4 mL of a 50% aqueous TFA solution and the mixture was stirred 
for 4 h. The solvent was evaporated and subsequently portioned between EtOAc/Et2O (1:1) 
and H2O. The organic phase was washed with H2O and the aqueous layers were combined 
and lyophilized. Purification of the crude mixture using RP high-performance liquid 
chromatography (HPLC, Phenomenex Luna C-18, H2O/0.1% HCOOH in CH3CN, 90:10 → 
0:100 in 23 min, flow 17.5 mL/min) afforded compound 7a as a white powder (14.1 mg, 
55%). 
1
H NMR (300 MHz, DMSO-d6): δ 1.40-1.43 (m, 2H, H-6’), 1.80-1.84 (m, 2H, H-5’), 
3.82-3.83 (m, 2H, H-3’, H-4’), 4.19 (t, J = 5.1 Hz, H-2’), 5.72 (d, J = 4.5 Hz, H-1’), 7.26-
7.40 (m, 3H, Ph), 7.51-7.54 (m, 2H, Ph), 7.64 (s, H-6). 
31
P NMR (DMSO-d6): δ 25.89. 
13
C 
NMR (75 MHz, DMSO-d6): δ 26.89 (C-5’), 72.46 (C-3’), 72.52 (C-2’), 83.59 (d, J = 15.9 Hz, 
C-4’), 89.54 (C-1’), 113.97 (C-5), 127.36, 128.16, 128.22, 132.80 (Ph), 138.34 (C-6), 150.11 
(C-2), 162.07 (C-4). HRMS (ESI) for C16H18N2O8P [M-H]
-





Reaction of compound 6b (70 mg, 0.073 mmol) with TMSBr (19 μL, 1.46 mmol), work-up 
and purification as described for 7a, afforded compound 7b as a white powder (22.6 mg, 
39%). 
1
H NMR (300 MHz, DMSO-d6): δ 1.60 (br s, 2H, H-6’), 1.78-1.84 (m, 2H, H-5’), 3.77-
3.85 (m, 2H, H-3’, H-4’), 4.25 (t, J = 5.4 Hz, H-2’), 5.73 (d, J = 4.8 Hz, H-1’), 7.29-7.41 (m, 
3H, naphthyl), 7.52-7.69 (m, 2H, naphthyl), 7.69 (s, H-6), 11.57 (s, 3-NH). 
31
P NMR 
(DMSO-d6): δ 25.71. 
13
C NMR (75 MHz, DMSO-d6): δ 23.80 (C-6’), 27.04 (C-5’), 72.56 (C-
3’), 72.62 (C-2’), 83.52 (C-4’), 89.83 (C-1’), 113.94 (C-5), 126.19, 126.27, 126.58, 126.78, 
127.50, 128.22, 130.51, 132.23, 132.91 (naphthyl), 138.95 (C-6), 150.21 (C-2), 162.32 (C-4). 
HRMS (ESI) for C20H20N2O8P [M-H]
-
 found, 447.0969; calcd, 447.0963. 
1-[5’,6’-Dideoxy-6’-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(4-
fluorophenyl)uracil (7c) 
Reaction of compound 6c (56 mg, 0.11 mmol) with TMSBr (29 μL, 2.20 mmol), work-up and 
purification as described for 7a, afforded compound 7c as a white powder (26.1 mg, 57%). 
1
H 
NMR (300 MHz, DMSO-d6): δ 1.62 (br s, 2H, H-6’), 1.79 (br s, 2H, H-5’), 3.77-3.84 (m, 2H, 
H-3’, H-4’), 4.26 (t, J = 5.1 Hz, H-2’), 5.73 (d, J = 4.8 Hz, H-1’), 7.21 (t, 2H, J = 8.7 Hz, 
Ph), 7.56-7.60 (m, 2H, Ph), 7.70 (s, H-6), 11.59 (s, 3-NH). 
31
P NMR (DMSO-d6): δ 26.17. 
13
C 
NMR (75 MHz, DMSO-d6): δ 27.05 (C-5’), 72.57 (C-3’), 72.60 (C-2’), 83.65 (C-4’), 89.67 
(C-1’), 113.11 (C-5), 114.92, 115.20, 129.21, 129.25, 130.29, 130.40 (Ph), 138.44 (C-6), 
150.18 (C-2), 160.01 (Ph), 162.17 (C-4). HRMS (ESI) for C16H17FN2O8P [M-H]
-
 found, 
415.0722; calcd, 415.0712. 
1-[5’,6’-Dideoxy-6’-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-styryluracil (7d) 
Reaction of compound 6d (72 mg, 0.14 mmol) with TMSBr (36 μL, 2.75 mmol), work-up and 
purification as described for 7a, afforded compound 7d as a white powder (6.5 mg, 11%). 
1
H 
NMR (300 MHz, DMSO-d6): δ 1.60 (br s, 2H, H-6’), 1.87 (br s, 2H, H-5’), 3.78-3.86 (m, 2H, 
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H-3’, H-4’), 4.15 (app s, H-2’), 5.75-5.76 (m, H-1’), 6.98 (d, J = 16.2 Hz, styryl), 7.15-7.57 
(m, 6H, styryl), 7.78 (s, H-6). 
31
P NMR (DMSO-d6): δ 24.42. 
13
C NMR (175 MHz, DMSO-
d6): δ 24.35 (C-6’), 27.07 (C-5’), 72.35 (C-3’), 72.72 (C-2’), 83.48 (C-4’), 88.68 (C-1’), 
111.27 (C-5), 121.28 (5-CH=CH-), 125.97 (Cortho), 127.27 (Cpara), 128.20 (5-CH=CH-), 
128.57 (Cmeta), 137.57 (Cipso), 138.78 (C-6), 149.62 (C-2), 162.04 (C-4). HRMS (ESI) for 
C18H20N2O8P [M-H]
-
 found, 423.0954; calcd, 423.0963. 
1-[5’,6’-Dideoxy-6’-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(p-tolyl)uracil (7e) 
Reaction of compound 6e (29 mg, 0.058 mmol) with TMSBr (15 μL, 1.15 mmol) work-up 
and purification as described for 7a, afforded compound 7e as a white powder (4.3 mg, 18%). 
1
H NMR (300 MHz, DMSO-d6): δ 1.40-1.99 (m, 4H, H-5’, H-6’), 3.77-3.82 (m, 2H, H-3’, H-
4’), 4.22 (m, H-2’), 5.73 (d, J = 4.5 Hz, H-1’), 7.19 (d, 2H, J = 7.5 Hz, p-tolyl), 7.42 (d, 2H, J 
= 7.8 Hz, p-tolyl), 7.62 (s, H-6). 
31
P NMR (DMSO-d6): δ 25.55. 
13
C NMR (75 MHz, DMSO-
d6): δ 20.61 (CH3), 27.00 (C-6’), 72.33 (C-3’), 72.42 (C-2’), 83.64 (C-4’), 89.28 (C-1’), 
113.74 (C-5), 127.85, 128.58, 129.71, 136.47 (p-tolyl), 137.58 (C-6), 149.92 (C-2), 161.95 
(C-4). HRMS (ESI) for C17H20N2O8P [M-H]
-
 found, 411.0970; calcd, 411.0963. 
1-[5’,6’-Dideoxy-6’-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(furan-2-yl)uracil 
(7f) 
Reaction of compound 6f (32 mg, 0.067 mmol) with TMSBr (18 μL, 1.34 mmol), work-up 
and purification as described for 7a, afforded compound 7f as a white powder (5.8 mg, 22%). 
1
H NMR (300 MHz, DMSO-d6): δ 1.61 (br s, 2H, H-6’), 1.83-1.91 (m, 2H, H-5’), 3.80-3.82 
(m, 2H, H-3’, H-4’), 4.12 (s, H-2’), 5.73 (d, J = 3.9 Hz, H-1’), 6.51 (d, J = 1.8 Hz, furanyl), 
6.87 (d, J = 3.3 Hz, furanyl), 7.66 (s, furanyl), 7.82 (s, H-6). 
31
P NMR (DMSO-d6): δ 25.08. 
13
C NMR (75 MHz, DMSO-d6): δ 27.12 (C-5’), 72.58, 73.34 (C-2’, C-3’), 83.56 (C-4’), 89.56 
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(C-1’), 105.69, 108.10, 111.56 (C-5, furanyl), 134.25 (C-6), 141.81, 146.08 (furanyl), 149.42 
(C-2), 160.07 (C-4). HRMS (ESI) for C14H16N2O9P [M-H]
-
 found, 387.0604; calcd, 387.0599. 
1-[5’,6’-Dideoxy-6’-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(thien-2-yl)uracil 
(7g) 
Reaction of compound 6g (32 mg, 0.063 mmol) with TMSBr (17 μL, 1.26 mmol), work-up 
and purification as described for 7a, afforded compound 7g as a white powder (9.3 mg, 37%). 
1
H NMR (300 MHz, DMSO-d6): δ 1.61 (br s, 2H, H-6’), 1.75-1.91 (m, 2H, H-5’), 3.80-3.85 
(m, 2H, m, H-3’, H-4’), 4.22-4.28 (m, H-2’), 5.71 (d, J = 4.5 Hz, H-1’), 7.02-7.10 (m, 
thienyl), 7.46 (d, J = 5.1 Hz, thienyl), 7.50 (s, thienyl), 7.96 (s, H-6). 
31
P NMR (DMSO-d6): δ 
25.42. 
13
C NMR (175 MHz, DMSO-d6): δ 24.21 (C-6’), 26.99 (C-5’), 72.36 (C-3’), 72.73 (C-
2’), 83.68 (C-4’),89.80 (C-1’), 108.63 (C-5), 123.20 (C-3”), 125.80 (C-5”), 126.54 (C-4”), 
133.39 (C-2”), 135.82 (C-6), 149.48 (C-2), 161.30 (C-4). HRMS (ESI) for C14H16N2O8PS [M-
H]
-
 found, 403.0343; calcd, 403.0371. 
1-[5’,6’-Dideoxy-6’-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(benzothiophen-3-
yl)uracil (7h) 
Reaction of compound 6h (49 mg, 0.088 mmol) with TMSBr (23 μL, 1.76 mmol), work-up 
and purification as described for 7a, afforded compound 7h as a white powder (31.5 mg, 
78%). 
1
H NMR (300 MHz, DMSO-d6): δ 1.59 (br s, 2H, H-6’), 1.76-1.80 (m, 2H, H-5’), 3.76-
3.83 (m, 2H, H-3’, H-4’), 4.21-4.4.24 (m, H-2’), 5.77 (d, J = 4.8 Hz, H-1’), 7.36-7.44 (m, 2H, 
benzothiophenyl), 7.63-7.66 (m, benzothiophenyl), 7.78 (app d, 2H, J = 7.2 Hz, 
benzothiophenyl, H-6), 7.98-8.02 (m, benzothiophenyl), 11.66 (s, 3-NH). 
31
P NMR (DMSO-
d6): δ 26.13. 
13
C NMR (75 MHz, DMSO-d6): δ 26.65 (C-5’), 72.49 (C-3’), 72.44 (C-2’), 
83.47 (C-4’), 89.37 (C-1’), 109.30 (C-5), 123.05, 124.28, 124.39, 126.65, 128.23, 138.02, 
29 
 
139.14, 139.68 (benzothiophenyl, C-6), 150.29 (C-2), 162.00 (C-4). HRMS (ESI) for 
C18H18N2O8PS [M-H]
-
 found, 453.0531; calcd, 453.0527. 
1-[5’,6’-Dideoxy-6’-(diethoxyphosphinyl)-β-D-ribo-hexofuranosyl]uracil (8)  
A solution of compound 4 (428 mg, 1.02 mmol) and 50% aq HCOOH (10 mL) was stirred for 
4.5 h at room temperature. The mixture was evaporated in vacuo and purified on a silica 
column using CH2Cl2/MeOH (90:10) as a solvent. Compound 8 was obtained as a colorless 
solid (220 mg, 57%). 
1
H NMR (300 MHz, DMSO-d6): δ 1.23 (t, 6H, J = 6.9 Hz, OCH2CH3), 
1.72-1.86 (m, 4H, H-5’, H-6’), 3.32-3.83 (m, 2H, H-3’, H-4’), 3.93-4.11 (m, 5H, OCH2CH3, 
H-2’), 5.12 (d, J = 5.7 Hz, 3’-OH), 5.35 (d, J = 5.7 Hz, 2’-OH), 5.63 (d, J = 8.1 Hz, 
CH=CH), 5.68 (d, J = 5.1 Hz, H-1’), 7.59 (d, J = 8.1 Hz, CH=CH), 11.34 (s, 3-NH). 
31
P 
NMR (DMSO-d6): δ 31.86. 
13
C NMR (75 MHz, DMSO-d6): δ 16.26, 16.33 (OCH2CH3), 
20.92 (d, J = 140 Hz, C-6’), 25.93 (C-5’), 60.93, 60.96 (d, J = 6 Hz, OCH2CH3), 72.48, 72.57 
(C-2’, C-3’), 82.65 (d, J = 17 Hz, C-4’), 88.93 (C-1’), 102.06 (C-5), 141.42 (C-6), 150.61 (C-
2), 163.03 (C-4). HRMS (ESI) for C14H24N2O8P [M+H]
+
 found, 379.1262; calcd, 379.1265. 
1-[2,2’-O-Anhydro-5’,6’-dideoxy-6’-(diethoxyphosphinyl)-β-D-arabinofuranosyl]uracil 
(9)  
Compound 8 (205 mg, 0.54 mmol) was dissolved into a mixture of thionyl chloride (0.17 mL) 
and CH3CN (1.4 mL) with vigorously stirring and then the reaction was maintained at room 
temperature. After 2 h, the mixture was poured into H2O and extracted with CH2Cl2. The 
combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. Without 
further purification, the 2’,3’-sulfonyl derivative of 8 and sodium acetate (223 mg, 2.72 
mmol) were heated in DMF at about 85 °C. After stirring for 3 h, solvents were removed in 
vacuo and the crude mixture purified on a silica gel column (CH2Cl2/MeOH (95:5 → 80:20)) 
yielding 180 mg (92%) of 9 as a white foam. 
1
H NMR (300 MHz, DMSO-d6): δ 1.14-1.23 (m, 
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7H, OCH2CH3, H-5’a), 1.59-1.68 (m, 3H, H-5’b, H-6’), 3.84-3.94 (m, 4H, OCH2CH3), 4.00-
4.10 (m, H-4’), 4.32 (app s, H-3’), 5.19 (d, J = 5.7 Hz, H-2’), 5.87 (d, J = 7.5 Hz, CH=CH), 
6.30 (d, J = 5.7 Hz, H-1’), 7.91 (d, J = 7.5 Hz, CH=CH). 
31
P NMR (DMSO-d6): δ 31.02. 
13
C 
NMR (75 MHz, CDCl3): δ 16.45, 16.53 (OCH2CH3), 22.04 (d, J = 143 Hz, C-6’), 26.42 (C-
5’), 62.14, 62.17 (d, J = 6.6 Hz, OCH2CH3), 87.72 (d, J = 16.7 Hz, C-4’), 89.49 (C-2’), 90.31 
(C-1’), 109.94 (C-5), 136.16 (C-6), 160.19 (C-2), 172.90 (C-4). HRMS (ESI) for 
C14H22N2O7P [M+H]
+
 found, 361.1157; calcd, 361.1159. 
1-[2’-Azido-2’-deoxy-5’,6’-dideoxy-6’-(ethoxyhydroxyphosphinyl)-β-D-ribo-
hexofuranosyl]uracil (10) 
A suspension of compound 9 (33 mg, 0.092 mmol) and NaN3 (37 mg, 0.56 mmol) in 0.7 mL 
DMF was heated overnight at 150 °C. The mixture was cooled to room temperature and 
evaporated in vacuo. The residue was dissolved in CH2Cl2/MeOH (8:2) and filtrated. Solvents 
were removed to afford compound 10 which was used in the next reaction without further 
purification (30 mg, 88%, yellow oil). 
1
H NMR (300 MHz, DMSO-d6): δ 1.08-1.20 (m, 3H, 
OCH2CH3), 1.48-1.70 (m, 2H, H-6’), 1.76-1.91 (m, 2H, H-5’), 3.75-3.89 (m, 3H, OCH2CH3, 
H-2’), 4.13-4.17 (m, H-4’), 4.24-4.26 (m, H-3’), 5.66-5.74 (m, 2H, H-1’, CH=CH), 7.94-8.02 
(m, CH=CH). 
31
P NMR (DMSO-d6): δ 25.36. HRMS (ESI) for C12H19N5O7P [M+H]
+
 found, 
376.0997; calcd, 376.1017. 
1-[2’-Amino-2’-deoxy-5’,6’-dideoxy-6’-(ethoxyhydroxyphosphinyl)-β-D-ribo-
hexofuranosyl]uracil (11) 
Compound 10 (24 mg, 0.065 mmol) and PPh3 (34 mg, 0.13 mmol) were dissolved in THF (1 
mL). After stirring for 10 minutes, H2O was added (17 μL). After stirring overnight, the 
volatiles were removed in vacuo. The residue dissolved in H2O, washed with EtOAc/Et2O 
(1:1) and lyophilized to yield 24 mg of crude 11 as a light yellow solid. 
1
H NMR (300 MHz, 
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DMSO-d6): δ 1.02-1.15 (m, 3H, OCH2CH3), 1.21-1.52 (m, 2H, H-6’), 1.76 (br s, 2H, H-5’), 
3.56-3.77 (m, 3H, OCH2CH3, H-2’), 4.04-4.10 (m, H-4’), 4.22 (app s, H-3’), 5.83-5.88 (m, 
CH=CH), 6.27 (app d, J = 5.4 Hz, H-1’), 7.91-7.93 (d, J = 7.5 Hz, CH=CH). 
31
P NMR (D2O-
d6): δ 26.76. HRMS (ESI) for C12H19N3O7P [M-H]
-
 found, 348.0954; calcd, 348.0966. 
1-[2’-Amino-2’-deoxy-5’,6’-dideoxy-6’-(dihydroxyphosphinyl)-β-D-ribo-
hexofuranosyl]uracil (12) 
To a solution of compound 11 (23.6 mg, 0.067mmol) in CH2Cl2 (2.0 mL) was added TMSBr 
(90 µL, 0.68 mmol). After stirring overnight, the volatiles were removed in vacuo. The 
residue was dissolved in H2O, washed with EtOAc/Et2O (1:1) and lyophilized. The residue 
was purified using flash chromatography (iPrOH/NH4OH/H2O 6:3:1) yielding compound 12 
(18.6 mg, 78%) as a light yellow powder. Compound 12 was isolated in the ammonium salt 
form. 
1
H NMR (300 MHz, D2O): δ 1.61-1.78 (m, 2H, H-6’), 1.89-1.95 (m, 2H, H-5’), 4.00-
4.01 (m, H-2’), 4.12-4.18 (m, H-4’), 4.34-4.37 (m, H-3’), 5.93 (d, J = 7.8 Hz, CH=CH), 6.06 
(app d, J = 6.6 Hz, H-1’), 7.73 (d, J = 8.4 Hz, CH=CH). 
31
P NMR (D2O-d6): δ 24.03. 
13
C 
NMR (75 MHz, D2O): δ 24.10 (d, J = 134 Hz, C-6’), 27.20 (d, J = 3.5 Hz, C-5’), 55.79 (C-
2’), 71.65 (C-3’), 86.20 (d, J = 17.3 Hz, C-4’), 87.27 (C-1’), 102.90 (C-5), 141.67 (C-6), 
151.88 (C-2), 166.21 (C-4). HRMS (ESI) for C10H15N3O7P [M-H]
-
 found, 320.0646; calcd, 
320.0653. 
1-[2’-Chloro-2’-deoxy-5’,6’-dideoxy-6’-(diethoxyhydroxyphosphinyl)-β-D-ribo-
hexofuranosyl]uracil (13)  
To a solution of compound 9 (76 mg, 0.21 mmol) in dry dioxane (0.5 mL) was added 2 N HCl 
in diethylether (1.4 mL). After stirring overnight, the mixture was concentrated in vacuo and 
the residue purified on a silica gel column (CH2Cl2/MeOH 90:10) affording compound 13 as a 
colorless solid (45 mg, 54%). 
1
H NMR (300 MHz, DMSO-d6): δ 1.23 (t, 6H, J = 7.2 Hz, 
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OCH2CH3), 1.65-1.98 (m, 4H, H-5’, H-6’), 3.87-3.89 (m, H-4’), 3.94-4.02 (m, 5H, OCH2CH3, 
H-3’), 4.73 (app t, J = 6.0 Hz, H-2’), 5.69 (d, J = 8.1 Hz, CH=CH), 5.89 (d, J = 5.1 Hz, 3’-
OH), 5.96 (d, J = 6Hz, H-1’), 7.63 (d, J = 8.4 Hz, CH=CH), 11.45 (s, 3-NH). 
31
P NMR 
(DMSO-d6): δ 32.03. 
13
C NMR (75 MHz, DMSO-d6): δ 16.43, 16.50 (OCH2CH3), 20.99 (d, J 
= 140 Hz, C-6’), 25.82 (d, J = 3.9 Hz, C-5’), 61.12 (C-2’), 61.20 (OCH2CH3), 71.93 (C-3’), 
83.57 (d, J = 17 Hz, C-4’), 88.83 (C-1’), 102.62 (C-5), 140.71 (C-6), 150.69 (C-2), 163.07 (C-
4). HRMS (ESI) for C14H23ClN2O7P [M+H]
+
 found, 397.0942; calcd, 397.0926. 
1-[2’-Chloro-2’-deoxy-5’,6’-dideoxy-6’-(dihydroxyphosphinyl)-β-D-ribo-
hexofuranosyl]uracil (14) 
To a solution of compound 13 (41 mg, 0.10 mmol) in CH2Cl2 (1.5 mL) was added TMSBr (27 
μL, 0.20 mmol). After stirring overnight, the volatiles were removed in vacuo. The residue 
was dissolved in H2O, washed with EtOAc/Et2O (1:1) and lyophilized. The residue was 
purified using flash chromatography (iPrOH/NH4OH/H2O 6:3:1) yielding 58% of compound 
14 (21.8 mg, white powder). Compound 14 was isolated in the ammonium salt form. 
1
H NMR 
(300 MHz, D2O): δ 1.60-1.82 (m, 2H, H-6’), 1.94-2.05 (m, 2H, H-5’), 4.13-4.19 (m, H-4’), 
4.27 (app t, J = 5.4 Hz, H-3’), 4.66 (app t, J = 5.1 Hz, H-2’), 5.92 (d, J = 8.4 Hz, CH=CH), 
6.08 (d, J = 4.8 Hz, H-1’), 7.71 (d, J = 8.1 Hz, CH=CH). 
31
P NMR (D2O): δ 24.24. 
13
C NMR 
(75 MHz, D2O): δ 24.17 (d, J =134 Hz, C-6’), 27.10 (d, J =3.8 Hz C-5’), 61.39 (C-2’), 72.56 
(C-3’), 84.25 (d, J =17.9 Hz C-4’), 90.27 (C-1’), 102.73 (C-5), 141.52 (C-6), 151.69 (C-2), 
166.25 (C-4). HRMS (ESI) for C10H13ClN2O7P [M-H]
-
 found, 339.0154; calcd, 339.0154. 
 (1’S,2’R,3’S,4’R,5’S)-1’-(Diisopropyl-phosphonoethenyl)-2’,3’-O-(isopropylidine)-4’-
(uracil-1-yl)-bicyclo[3.1.0]hexane (16) 
Di-isopropyl azodicarboxylate (93 μL, 0.47 mmol) was added at rt to a mixture of 
triphenylphosphine (123 mg, 0.47 mmol) and 3-N-benzoyluracil (101 mg, 0.47 mmol) in 
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anhydrous THF (3 mL). After stirring for 40 min, a solution of compound 15
22
 (85 mg, 0.23 
mmol) in anhydrous THF (3 mL) was added to the mixture. After stirring for 36 h, the 
reaction mixture was evaporated to dryness. The resulting residue was purified by silica gel 
column chromatography (0-6% MeOH in EtOAc) to afford N-3-benzoyl protected uracil 
nucleoside as a white solid material (Rf =0.4, EtOAc/MeOH 94:6), which was treated with 6 
N NH3/MeOH (6 mL) and heated up to 50 ºC. After stirring for 19 h, the reaction mixture was 
evaporated to dryness. The resulting residue was purified by silica gel column 
chromatography (0-8% MeOH in CH2Cl2) to afford phosphonate diester 16 (25 mg, 24%) as a 
white solid material. Rf = 0.3 (CH2Cl2/MeOH 92:8). 
1
H NMR (CDCl3): δ 0.72-0.80 (m), 0.89-
0.95 (m), 1.24 (s, 3H), 1.28-1.33 (m, 12 H), 1.35-1.39 (m), 1.48 (s, 3H), 1.60-2.04 (m, 4H), 
4.33 (s), 4.64-4.72 (m, 3H), 4.91 (d, J = 7.1 Hz), 5.70 (d, J = 7.69 Hz), 7.14 (d, J = 7.69 Hz), 
8.25 (s, NH). HRMS (ESI) for C21H34N2O7P [M+H]
+
 found, 457.2121; calcd, 457.2104.  
(1’S,2’R,3’S,4’R,5’S)-2’,3’-(Dihydroxy)-1’-(phosphonoethenyl)-4’-(uracil-1-yl)-
bicyclo[3.1.0]hexane (17) 
Nucleoside 16 (22 mg, 0.048 mmol) was co-evaporated with anhydrous toluene (3× 2 mL) 
and dissolved in anhydrous CH2Cl2 (2 mL). Iodotrimethylsilane (96 μL, 0.48 mmol) was 
added. After stirring for 15 h, the reaction mixture was cooled to 0 ºC followed by the 
addition of ice-cold H2O (15 mL) and CH2Cl2 (15 mL). The phases were separated, and the 
aqueous phase was washed with CH2Cl2 (25mL) and diethylether (3 × 35 mL). The resulting 
aqueous phase was evaporated to dryness and purified by RP-HPLC (Phenomenex Luna C-
18, 10 mM triethylammonium acetate (TEAA)-CH3CN, 100:0 → 70:30 in 30 min, flow 3 
mL/min) to afford compound 17 (2.89 mg, 19%) as a white solid material. Compound 17 was 
isolated in the triethylammonium salt form. 
1
H NMR (D2O, 300 MHz): δ 0.72-0.80 (m, 1H), 
1.12-1.17 (m), 1.36-1.46 (m), 1.54-2.03 (m, 4H), 4.00 (d, J = 6.60 Hz), 4.46 (d, J = 6.60 Hz), 
34 
 
4.62 (s), 5.86 (d, J = 8.25 Hz), 7.61 (d, J = 8.25 Hz). 
31
P NMR (D2O): δ 26.82. HRMS (ESI) 
for C12H16N2O7P [M-H]
-
 found, 331.0682; calcd, 331.0695.  
2’,3’-Dideoxy-3’-phenylselenyl-5’-[(diethoxyphosphinyl)-methoxy]-β-D-uridine (19) 
A solution of phenylselenyl chloride (44 mg, 0.23 mmol) in CH2Cl2 (0.1 mL) was added 
dropwise to a solution of glycal 18
25
 (41 mg, 0.23 mmol) in CH2Cl2 (0.7 mL). After the 
mixture was stirred at -70 °C for 1 h, the solvent was removed under reduced pressure and the 
residue redissolved in CH2Cl2 (0.5 mL). Dimethyl(hydroxylmethyl)phosphonate (74 μL, 0.50 
mmol) was added and the solution was cooled to -70 °C. Over 3 minutes a solution of silver 
perchlorate (52 mg, 0.25 mmol) in CH3CN (0.1 mL) was added and the mixture was allowed 
to warm to 0 °C and poured into an aq. NaHCO3 solution. The organic phase was separated, 
dried over MgSO4 and evaporated in vacuo. The residual oil was chromatographed on silica 
(CH2Cl2/MeOH 96:4) yielding compound 19 (40 mg, 35%) as a colorless solid. 
1
H NMR (300 
MHz, CDCl3): δ 1.26 (app dt, 6H, J = 1.5, 7.2 Hz, OCH2CH3), 2.41-2.45 (m, 2H, H-2’), 3.59-
3.67 (m, H-5’a), 3.79-3.90 (m, 2H, H-5’b, H-3’), 4.03-4.13 (m, 4H, OCH2CH3), 5.09 (app s, 
H-4’), 5.74 (app dd, J = 2.4, 8.4 Hz, CH=CH), 6.48 (app t, J = 7.2 Hz, H-1’), 7.23-7.33 (m, 
3H, Ph), 7.49-7.55 (m, 2H, Ph), 7.61 (d, J = 8.4 Hz, CH=CH), 8.51 (s, 3-NH). 
31
P NMR 
(CDCl3): δ 20.12. 
13
C NMR (75 MHz, CDCl3): δ 16.65, 16.72 (OCH2CH3), 36.27 (C-2’), 
43.79 (C-3’), 60.47 (C-5’), 62.82, 62.91 (OCH2CH3), 86.53 (C-1’), 103.84 (C-4’), 110.04 (C-
5), 127.36, 128.89, 129.73, 135.12 (Ph), 140.41 (C-6), 150.51 (C-2), 162.78 (C-4). HRMS 
(ESI) for C19H26N2O7PSe [M+H]
+
 found, 505.0630; calcd, 505.0637. 
2’,3’-Dihydro-5’-[(diethoxyphosphinyl)methoxy]-β-D-uridine (20) 
To a solution of compound 19 (41 mg, 0.082 mmol) in MeOH (0.7 mL) was added dropwise a 
suspended solution of sodium bicarbonate (12 mg, 0.14 mmol) and sodium periodate (22 mg, 
0.10 mmol) in H2O (0.7 mL). After being stirred at rt for 1 h, the mixture was heated at 80 °C 
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for 75 min. Volatiles were removed in vacuo and the residue was suspended in CH2Cl2, 
filtered through celite and dried over MgSO4. After evaporation under reduced pressure, the 
residue was purified on a silica gel column (CH2Cl2/MeOH 96:4) to give compound 20 (19 
mg, 68%) as a yellow oil. 
1
H NMR (300 MHz, CDCl3): δ 1.31-1.36 (m, 6H, OCH2CH3), 3.87-
3.94 (m, H-5’a), 4.03-4.22 (m, 5H, H-5’b, OCH2CH3), 5.71 (d, J = 7.8 Hz, CH=CH), 5.80 
(app s, H-4’), 6.10 (app d, J = 6.0 Hz, H-2’), 6.28-6.31 (m, H-3’), 6.97 (app s, H-1’), 7.39 (d, 
J = 8.1 Hz, CH=CH), 9.21 (s, 3-NH). 
31
P NMR (CDCl3): δ 20.21. 
13
C NMR (75 MHz, 
CDCl3): δ 16.18, 16.25 (OCH2CH3), 61.17, 62.36, 63.41 (OCH2CH3, C-5’), 87.77 (C-1’), 
102.92 (C-5), 108.30, 108.46 (C-4’), 130.11 (C-2’), 131.73 (C-3’), 139.77 (C-6), 150.21 (C-
2), 162.78 (C-4). HRMS (ESI) for C13H20N2O7P [M+H]
+
 found, 347.0999; calcd, 347.1003. 
5’-[(Diethoxyphosphinyl)methoxy]-β-D-uridine (21) 
Compound 20 (37 mg, 0.11 mmol) was dissolved in a 5:1 acetone- H2O mixture (4 mL) and 
treated with osmium tetraoxide (0.19 mL [4 wt% solution], 0.032 mmol) and N-
methylmorpholine-N-oxide (32 mg, 0.26 mmol). After stirring for 48 h, the mixture was 
quenched with a saturated solution of Na2S2O3 (4 mL) and stirred for 30 min. The black 
mixture was extracted with EtOAc three times and the combined organic layers were dried 
over MgSO4 and evaporated. Chromatography of the residue on silica gel (CH2Cl2/MeOH 
90:10) yielded diol 21 as a colorless solid (24 mg, 60%). 
1
H NMR (300 MHz, DMSO-d6): δ 
1.23 (t, 6H, J = 6.9 Hz, OCH2CH3), 3.88-3.91 (m, 3H, H-3’, H-5’a, H-5’b), 4.02-4.10 (m, 4H, 
OCH2CH3), 4.93 (app s, H-4’), 5.52 (d, J = 6.0 Hz, 2’-OH), 5.60 (d, J = 4.2 Hz, 3’-OH), 5.65 
(d, J = 8.1 Hz, CH=CH), 6.06 (d, J = 6.9 Hz, H-1’), 7.49 (d, J = 8.1 Hz, CH=CH). 
31
P NMR 
(DMSO-d6): δ 20.55. 
13
C NMR (75 MHz, DMSO-d6): δ 16.44, 16.51 (OCH2CH3), 59.50 (C-
5’), 62.35, 62.43 (OCH2CH3), 73.07 (C-2’), 73.53 (C-3’), 87.78 (C-1’), 103.17 (C-5), 107.87, 
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108.03 (C-4’), 140.47 (C-6), 151.13 (C-2), 163.12 (C-4). HRMS (ESI) for C13H22N2O9P 
[M+H]
+
 found, 381.1035; calcd, 381.1057. 
5’-[(Dihydroxyphosphinyl)methoxy]-β-D-uridine (22) 
Compound 18 (23 mg, 0.061 mmol) was dissolved in dry DMF (3.8 mL) and cooled to 0 °C. 
The solution was then treated with 2,6-lutidine (71 μL, 0.61 mmol) followed by the dropwise 
addition of TMSBr (41 μL, 0.30 mmol). The mixture was allowed to warm to rt and stirred 
for 16 h. The solvent was evaporated and subsequently portioned between EtOAc/Et2O (1:1) 
and H2O. The organic phase was washed with H2O and the aqueous layers were combined 
and lyophilized. The residue was purified using flash chromatography (iPrOH/NH4OH/H2O 
6:3:1) yielding compound 22 (9.0 mg, 50%) as a white powder. 
1
H NMR (300 MHz, 
CD3OD): δ 3.47-3.55 (m, H-5’a), 3.80-3.87 (m, H-5’b), 4.09 (app d, J = 4.2 Hz, H-3’), 4.40-
4.44 (m, H-2’), 4.96 (H-4’), 5.84 (d, J = 8.1 Hz, CH=CH), 6.25 (d, J = 6.6 Hz, H-1’), 7.91 (d, 
J = 7.8 Hz, CH=CH). 
31
P NMR (CD3OD): δ 14.09. 
13
C NMR (75 MHz, CD3OD): δ 64.88 (C-
5’), 66.99 (C-2’), 73.62 (C-3’), 89.86 (C-1’), 104.15 (C-5), 110.31, 110.49 (C-4’), 143.28 (C-
6), 152.96 (C-2), 166.08 (C-4). HRMS (ESI) for C9H12N2O9P [M-H]
-
 found, 323.0296; calcd, 
323.0286. 
Assay of PLC activity  
Stable cell lines for study of the human P2Y2, P2Y4, and P2Y6 receptors were generated by 
retroviral expression of the receptor in 1321N1 human astrocytoma cells, which do not 




H]inositol phosphate production was 
measured in cells plated at 20,000 cells/well on 96-well plates two days prior to assay. Sixteen 
h before the assay, the inositol lipid pool of the cells was radiolabeled by incubation in 100 
μL of serum-free inositol-free Dulbecco's modified Eagle's medium, containing 1.0 μCi of 
[
3





H]inositol. On the day of the assay, cells were challenged with 25 μL of a five-fold 
concentrated solution of receptor agonists in 100 mM Hepes (N-(2-hydroxyethyl)-piperazine-
N-2-ethanesulfonic acid), pH 7.3 in HBSS, containing 50 mM LiCl for 30 min at 37C. 
Incubations were terminated by aspiration of the drug-containing medium and addition of 90 
μL of ice-cold 50 mM formic acid. After 30 min, supernatants were neutralized with 30 μL of 
150 mM NH4OH and applied to Dowex AG1-X8 anion exchange columns. Total inositol 
phosphates were eluted and radioactivity was measured using a liquid scintillation counter.
27 
Data Analysis 
Agonist potencies (EC50 values) were determined from concentration-response curves by non-
linear regression analysis using the GraphPad software package Prism (GraphPad, San Diego, 
CA). Each concentration of drug was tested in triplicate assays, and concentration effect 
curves for each test drug were repeated in at least three separate experiments with freshly 
diluted molecule. The results are presented as mean ± SEM from multiple experiments or in 
the case of concentration effect curves from a single experiment carried out with triplicate 
assays that were representative of results from multiple experiments. 
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